133 related articles for article (PubMed ID: 30905520)
1. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Kásler M; Forster T
Int J Cardiol; 2019 Jun; 285():47-52. PubMed ID: 30905520
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
Banke A; Fosbøl EL; Møller JE; Gislason GH; Andersen M; Bernsdorf M; Jensen MB; Schou M; Ejlertsen B
Eur J Heart Fail; 2018 Oct; 20(10):1447-1453. PubMed ID: 29493047
[TBL] [Abstract][Full Text] [Related]
3. [Analysing the risk factors of doxorubicin-associated heart failure by a retrospective study of integrated, nation-wide databases].
Fogarassy G; Fogarassyné Vathy Á; Kováts T; Hornyák L; Kenessey I; Veress G; Polgár C; Forster T
Orv Hetil; 2020 Jun; 161(26):1094-1102. PubMed ID: 32541088
[TBL] [Abstract][Full Text] [Related]
4. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
5. Preventing cancer therapy-related heart failure: the need for novel studies.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Veress G; Polgár C; Forster T
J Cardiovasc Med (Hagerstown); 2021 Jun; 22(6):459-468. PubMed ID: 32941327
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
[TBL] [Abstract][Full Text] [Related]
7. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
8. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
9. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
Basser RL; Abraham R; To LB; Fox RM; Green MD
Ann Oncol; 1999 Jan; 10(1):53-8. PubMed ID: 10076722
[TBL] [Abstract][Full Text] [Related]
10. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
11. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
Jensen BV; Skovsgaard T; Nielsen SL
Ann Oncol; 2002 May; 13(5):699-709. PubMed ID: 12075737
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
Gennari A; Salvadori B; Donati S; Bengala C; Orlandini C; Danesi R; Del Tacca M; Bruzzi P; Conte PF
J Clin Oncol; 1999 Nov; 17(11):3596-602. PubMed ID: 10550159
[TBL] [Abstract][Full Text] [Related]
13. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
14. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
15. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
[TBL] [Abstract][Full Text] [Related]
16. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.
Appel JM; Zerahn B; Møller S; Christensen HM; Søgaard P; Ejlertsen B; Fogh-Andersen N; Jensen BV; Nielsen DL
Acta Oncol; 2012 Nov; 51(8):1054-61. PubMed ID: 22909389
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
Lee YR; Kang MH; Park HM
Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
[TBL] [Abstract][Full Text] [Related]
18. Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure.
Schaadt B; Kelbaek H
J Nucl Cardiol; 1997; 4(6):494-501. PubMed ID: 9456189
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
[TBL] [Abstract][Full Text] [Related]
20. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer.
Saiki H; Petersen IA; Scott CG; Bailey KR; Dunlay SM; Finley RR; Ruddy KJ; Yan E; Redfield MM
Circulation; 2017 Apr; 135(15):1388-1396. PubMed ID: 28132957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]